

PROTECTING **HEART** 
BEYOND **BP CONTROL**



In Hypertension with HF and CAD

Affobis[®]
Bisoprolol Fumarate 1.25/2.5/5/10mg Tablets



In Hypertension with HF and CAD



Background:

Bisoprolol, a highly selective beta-1 blocker, has demonstrated significant efficacy in managing cardiovascular conditions, particularly in patients with heart failure, left ventricular hypertrophy, and coronary artery disease (CAD). Clinical studies show that Bisoprolol not only enhances cardiovascular survival but also offers superior heart rate reduction compared to other beta-blockers, making it a preferred choice for many heart failure patients. The medication's ability to reduce both heart rate and blood pressure leads to better heart function and lower mortality rates.

Available strengths

Affobis (Bisoprolol 1.25 / 2.5 / 5 / 10 mg Tablets)

Indication:

Affobis is indicated **In Hypertension with Heart Failure & Coronary Artery Disease**

Mechanism of Action:

Bisoprolol selectively blocks beta-1 receptors in the heart, leading to a reduction in heart rate and blood pressure. This helps in improving heart function, relieving strain on the heart, and enhancing overall cardiovascular stability.

Dosage:

1 tablet daily, or as prescribed by the doctor.

Unique Selling Points :

- Higher Beta-1 Selectivity:** Bisoprolol offers superior beta-1 receptor selectivity and a longer half-life compared to metoprolol.
- Heart Failure Benefits:** Proven to improve survival rates in heart failure patients.
- Enhanced Heart Rate Reduction:** Provides superior heart rate control and is equally effective in reducing blood pressure compared to other beta-blockers.
- Reduced Mortality:** Significantly lowers all-cause mortality rates in patients with heart failure and hypertension.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51(50 lines)
Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com



2025 All rights reserved, Medicamen Lifesciences Pvt Ltd

Combination Therapy for Better Cardio Protection



In Hypertension Management

Rx **Affobis[®] AM $\frac{2.5}{5}$**

Bisoprolol Fumarate 2.5/ 5 mg + Amlodipine 5 mg Tablets



In Hypertension Management



Bisoprolol Fumarate 2.5/5 mg + Amlodipine 5 mg Tablets

Background:

The combination of Bisoprolol, a highly selective beta-1 blocker, and Amlodipine, a calcium channel blocker, offers a robust solution for managing hypertension. This dual-action approach targets both heart rate and blood pressure, working synergistically to improve cardiovascular health. Bisoprolol reduces heart rate and decreases blood pressure by blocking beta-1 receptors, while Amlodipine provides vascular relaxation through calcium channel blockade. Together, they provide enhanced blood pressure control, reduce strain on the heart, and contribute to better overall cardiovascular function.

Available Strengths:

Affobis- AM (Bisoprolol 2.5/5 mg + Amlodipine 5 mg Tablets)

Indication:

Affobis-AM is indicated In Hypertension Management

Mechanism of Action:

- **Bisoprolol** selectively blocks beta-1 receptors in the heart, reducing heart rate and blood pressure, which improves heart function and reduces strain.
- **Amlodipine** works by inhibiting calcium ions from entering vascular smooth muscle, resulting in vasodilation, which reduces blood pressure and alleviates heart workload.

Dosage:

1 tablet daily, or as prescribed by the doctor.

Unique Selling Points (USP):

- **Dual Action for Hypertension Control:** Bisoprolol reduces heart rate, while Amlodipine lowers blood pressure, providing comprehensive hypertension management.
- **Superior Beta-1 Selectivity:** Bisoprolol offers targeted heart rate control with a longer half-life compared to other beta-blockers.
- **Effective Blood Pressure Reduction:** Amlodipine's vasodilation effect enhances blood pressure control for up to 24hours.
- **Improved Cardiovascular Health:** The combination reduces heart strain and supports overall heart function.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51(50 lines)

Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com



.....
.....
.....

2025 All rights reserved, Medicamen Lifesciences Pvt Ltd

Empowering Heart Health with Dual Action



In Hypertension with CAD/Post MI & Heart Failure

Rx **Affobis® T $\frac{2.5}{5}$**

Bisoprolol Fumarate 2.5/ 5 mg + Telmisartan 40 mg Tablets





Background:

The combination of Angiotensin Receptor Blockers (ARBs) and Beta-blockers has been proven effective in reducing cardiovascular events, particularly in patients with left ventricular hypertrophy, coronary artery disease (CAD), and heart failure. Clinical evidence highlights that the combined use of an ARB and a Beta-blocker leads to superior cardiovascular survival outcomes compared to monotherapy or other antihypertensive treatments. This combination therapy results in the lowest risk of cardiovascular and overall mortality, due to the synergistic actions of each medication. By utilizing the strengths of both drug classes, patients can benefit from enhanced therapeutic effects.

Available Strengths

- ✓ Bisoprolol 2.5 + Telmisartan 40 mg Tablets
- ✓ Bisoprolol 5 mg + Telmisartan 40 mg Tablets

Indication:

Affobis T is indicated in hypertension with Coronary Artery Disease (CAD) / Post MI & Heart Failure.

Mechanism of Action:

- ✓ Telmisartan works by inhibiting the action of angiotensin II, blocking its binding to the AT1 receptor, and thus reducing vasoconstriction and aldosterone release in key tissues such as blood vessels and the adrenal glands.
- ✓ Bisoprolol, a highly selective beta-1 blocker, primarily affects the heart by lowering heart rate and reducing blood pressure, ultimately improving cardiovascular stability and reducing strain on the heart.

Dosage:

Affobis T: Take 1-2 tablets daily, or as prescribed by the doctor.

Unique Selling Points (USP):

Bisoprolol:

- ✓ Offers higher beta-1 selectivity and a longer half-life compared to metoprolol.
- ✓ Demonstrates survival benefits in patients with heart failure.
- ✓ Provides superior heart rate reduction and comparable blood pressure control versus metoprolol.
- ✓ Significantly lowers all-cause mortality rates.

Telmisartan:


- ✓ Extended half-life for prolonged effect.
- ✓ Provides continuous, 24-hour blood pressure management.
- ✓ Delivers cardiovascular protection with improved patient tolerance.
- ✓ Effective in managing the progression of metabolic syndrome.



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51(50 lines)

Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com



2025 All rights reserved, Medicamen Lifesciences Pvt Ltd